SunRISe-1: TAR-200 and Cetrelimab in Patients With High-Risk NMIBC
Following a review of the limitations of current treatment options, Neal Shore, MD, MFACS, discusses the SunRISe-1 trial investigating TAR-200 plus cetrelimab in patients with high-risk NMIBC.
EP: 1.Overview of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC)
EP: 2.Treating Patients With High-Risk BCG-Unresponsive NMIBC
EP: 3.SunRISe-1: TAR-200 and Cetrelimab in Patients With High-Risk NMIBC
EP: 4.Ongoing Research in BCG-Unresponsive NMIBC
EP: 5.What Are the Advantages of TAR-200 in BCG-Unresponsive NMIBC?
EP: 6.Emerging Agents in BCG-Unresponsive NMIBC
EP: 7.Optimizing Patient Selection and Treatment Sequencing in BCG-Unresponsive NMIBC
This is a video synopsis/summary of an Investigator Perspectives featuring Neal Shore, MD, FACS.
Dr Shore discusses limitations of current treatments for high-risk non–muscle-invasive bladder cancer (NMIBC). Bacillus Calmette-Guérin (BCG) shortages occur, and manufacturing complexity contributes. Intravesical chemotherapy has more success in intermediate-risk patients. With high-risk disease, bladder removal (cystectomy) is often recommended, which has risks including mortality.
The SunRISe-1 trial is evaluating an investigational drug delivery device called TAR-200, which provides sustained-release gemcitabine directly into the bladder vs standard intravesical chemotherapy. Early results presented at the American Urological Association 2023 Annual Meeting showed approximately 90% complete response at 3 months and approximately 80% at 6 months when TAR-200 is used as monotherapy in BCG-unresponsive, high-risk NMIBC patients who refused or were ineligible for cystectomy. TAR-200 is also being studied with cetrelimab, a PD-1 checkpoint inhibitor.
The patients enrolled have received at least 5 of 6 BCG induction courses plus 2 of 3 maintenance courses, meeting criteria for BCG-unresponsive disease. They refused or were ineligible for cystectomy, often due to comorbidities. The TAR-200 device is easily placed and removed in the clinic setting without need for systemic anesthesia.
Video synopsis is AI-generated and reviewed by Urology Times® editorial staff.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.
